For example, large phase III breast cancer trials in the early 2000s, such as MA.17 (NCT00003140), HERA (NCT00045032) and BIG 1-98 (NCT00004205), all included allowance for crossover, but did not have trial sites within the US [21–23]. Here, ERAL1 is linked to breast carcinoma.